
BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Mestastop Solutions applies to CDSCO for approval of Ph II clinical trial targeting metastasis

16 May 2025 | News

Mestastop is collaborating on the trial with Raptim Research



Bengaluru-based biotech startup Mestastop Solutions, which focuses on cancer metastasis, has filed for approval of its first clinical candidate for a Phase II study to delay metastasis in adjuvant settings for patients with primary colorectal cancer tumours.

Founded in 2018, the company has dedicated significant time to understanding metastasis biology using primary tumour patient samples in collaboration with the Rajiv Gandhi Cancer Institute.

Mestastop is collaborating on this trial with Raptim Research, a Mumbai-based contract research organisation (CRO). Raptim has conducted over 50 late-stage trials in multiple therapeutic areas and has also cleared more than nine US FDA inspections for late-phase oncology trials.

Mestastop aims to conduct this trial on sixty primary colorectal cancer patients who have undergone surgery and/or chemotherapy. The randomised controlled, double-blinded trial is expected to run for at least two years, and the company intends to initiate patient recruitment as soon as approval is received.

Dr. Arnab Roy Chowdhury, founder and director of Mestastop, said "The novelty of the Mestastop approach in preventing cells from colonising in the secondary axis has a tremendous potential to impact how we treat cancer, and we all believe that this will help a lot of patients in the future."

2025 has been an eventful year for Mestastop. Two of its initial patents have been approved in India and the USA, and the company has also filed for two new international patents for its two potential clinical candidates. It is currently working on a novel discovery programme with a first-in-class target for metastasis and will present new data at the upcoming European Association of Cancer Research meeting in June 2025.